NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that its Phase II/III clinical trial to assess the efficacy and safety of its NFL-101 smoking cessation treatment has been approved by the French National Agency for the Safety of Medicines and Health Products […]
